Previously, we observed significant increases in spinal
12-lipoxygenase (LOX) metabolites, in particular, hepoxilins, which contribute to peripheral
inflammation-induced
tactile allodynia. However, the enzymatic sources of
hepoxilin synthase (HXS) activity in rats remain elusive. Therefore, we overexpressed each of the 6 rat 12/15-LOX
enzymes in HEK-293T cells and measured by LC-MS/MS the formation of HXB3,
12-HETE,
8-HETE, and
15-HETE from
arachidonic acid (AA) at baseline and in the presence of LOX inhibitors (NDGA,
AA-861, CDC,
baicalein, and PD146176) vs. vehicle-treated and mock-transfected controls. We detected the following primary intrinsic activities: 12-LOX (Alox12, Alox15), 15-LOX (Alox15b), and HXS (Alox12, Alox15). Similar to human and mouse orthologs,
proteins encoded by rat Alox12b and Alox12e possessed minimal 12-LOX activity with AA as substrate, while eLOX3 (encoded by Aloxe3) exhibited HXS without 12-LOX activity when coexpressed with Alox12b or supplemented with
12-HpETE. CDC potently inhibited HXS and 12-LOX activity in vitro (relative IC50s: CDC, ~0.5 and 0.8 μM, respectively) and
carrageenan-evoked
tactile allodynia in vivo. Notably, peripheral
inflammation significantly increased spinal eLOX3; intrathecal pretreatment with either
siRNA targeting Aloxe3 or an eLOX3-selective antibody attenuated the associated
allodynia. These findings implicate spinal eLOX3-mediated hepoxilin synthesis in inflammatory
hyperesthesia and underscore the importance of developing more selective 12-LOX/HXS inhibitors.